Company: TBPH
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001558370-25-007398
Chunk: 2

Company: Theravance Biopharma, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1F
Chunk 2
---
ITEM 1.    FINANCIAL STATEMENTS

​

THERAVANCE BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except per share data)

​​​​​​​​​March 31, ​December 31, ​    2025    2024Assets​​​​​​Current assets:​​​​​​Cash and cash equivalents ​$ 110,614​$ 37,797Short-term marketable securities​  20,241​  50,553Receivables from collaborative arrangements ​  15,353​  18,440Receivables from milestones and royalty assets​​ —​​ 50,000Other prepaid and current assets  ​​ 4,056​​ 4,277Total current assets ​  150,264​  161,067Property and equipment, net ​  7,028​  7,418Operating lease assets​​ 27,430​​ 28,354Future contingent milestone and royalty assets​​ 144,200​​ 144,200Restricted cash ​  836​  836Other assets​​ 13,824​​ 12,286Total assets ​$ 343,582​$ 354,161​​​​​​​Liabilities and Shareholders' Equity​​​​​​Current liabilities:​​​​​​Accounts payable ​$ 2,408​$ 2,242Accrued personnel-related expenses ​  5,386​  7,019Accrued clinical and development expenses ​  2,457​  1,058Accrued general and administrative expenses​​ 2,520​​ 2,987Operating lease liabilities​​ 10,807​​ 10,712Income tax payable​​ 5,853​​ 5,853Other accrued liabilities​  2,071​  2,214Total current liabilities ​  31,502​  32,085Long-term operating lease liabilities​​ 37,349​​ 39,108Future royalty payment contingency​​ 30,977​​ 30,334Unrecognized tax benefits​​ 76,484​​ 75,199Other long-term liabilities​​ 1,287​​ 1,890Commitments and contingencies (Note 10)​​​​​​​​​​​​​Shareholders’ Equity​​​​​​Preferred shares, $0.00001 par value per share: 230 shares authorized, no shares issued or